Literature DB >> 9200005

Inhibition of bone resorption by pamidronate cannot restore normal gain in cortical bone mass and strength in tail-suspended rapidly growing rats.

Y Kodama1, K Nakayama, H Fuse, S Fukumoto, H Kawahara, H Takahashi, T Kurokawa, C Sekiguchi, T Nakamura, T Matsumoto.   

Abstract

To clarify how the changes in bone formation and resorption affect bone volume and strength after mechanical unloading, the effect of inhibition of bone resorption by a potent bisphosphonate, pamidronate, on bone mineral density (BMD), histology, and strength of hind limb bones was examined using tail-suspended growing rats. Tail suspension for 14 days reduced the gain in the BMD of the femur at both the metaphysis rich in trabecular bone and the diaphysis rich in cortical bone. Treatment with pamidronate increased the total BMD as well as that of the metaphysis of the femur but had almost no effect on the BMD of the diaphysis in both control and tail-suspended rats. Histological examinations revealed that 14-day tail suspension caused a loss of secondary cancellous bone with a reduction in the trabecular number and thickness in comparison with control rats. In the femoral diaphysis, the diameter and cortical bone thickness increased to a lesser degree in tail-suspended rats when compared with rats without tail suspension, and a marked reduction in bone formation and the layers of alkaline phosphatase-positive cells was observed at the periosteal side. Pamidronate treatment increased secondary cancellous bone but could not restore normal growth-induced periosteal bone apposition and bone strength. Because the material strength of the femoral diaphysis at the tissue level was not affected by pamidronate treatment, the inability of pamidronate to prevent the reduction in physical strength of the femoral diaphysis does not appear to be due to a change in the quality of newly formed bone. These results demonstrate that tail suspension reduces the growth-induced periosteal modelling drift and that the antiresorptive agent pamidronate is unable to restore normal periosteal bone apposition.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9200005     DOI: 10.1359/jbmr.1997.12.7.1058

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  16 in total

1.  Three-year effectiveness of intravenous pamidronate versus pamidronate plus slow-release sodium fluoride for postmenopausal osteoporosis.

Authors:  N Morabito; A Gaudio; A Lasco; C Vergara; F Tallarida; G Crisafulli; A Trifiletti; M Cincotta; M A Pizzoleo; N Frisina
Journal:  Osteoporos Int       Date:  2003-05-15       Impact factor: 4.507

2.  Zoledronic acid administration failed to prevent bone loss at the knee in persons with acute spinal cord injury: an observational cohort study.

Authors:  William A Bauman; Christopher M Cirnigliaro; Michael F La Fountaine; LeighAnn Martinez; Steven C Kirshblum; Ann M Spungen
Journal:  J Bone Miner Metab       Date:  2014-08-27       Impact factor: 2.626

3.  Effects of skeletal unloading on the vasomotor properties of the rat femur principal nutrient artery.

Authors:  Rhonda D Prisby; Bradley J Behnke; Matthew R Allen; Michael D Delp
Journal:  J Appl Physiol (1985)       Date:  2015-01-29

4.  Whole-body vibration and resistance exercise prevent long-term hindlimb unloading-induced bone loss: independent and interactive effects.

Authors:  Zhili Li; Cheng Tan; Yonghua Wu; Ye Ding; Huijuan Wang; Wenjuan Chen; Yu Zhu; Honglei Ma; Honghui Yang; Wenbin Liang; Shizhong Jiang; Desheng Wang; Linjie Wang; Guohua Tang; Jun Wang
Journal:  Eur J Appl Physiol       Date:  2012-02-28       Impact factor: 3.078

5.  Efficacy of Daily Teriparatide Treatment in Low Levels of Walking State Patients.

Authors:  Rui Niimi; Toshibumi Kono; Atsushi Nishihara; Masahiro Hasegawa; Toshihiko Kono; Akihiro Sudo
Journal:  Clin Drug Investig       Date:  2017-06       Impact factor: 2.859

6.  Effects of risedronate on femoral bone mineral density and bone strength in sciatic neurectomized young rats.

Authors:  Jun Iwamoto; Azusa Seki; Tsuyoshi Takeda; Yoshihiro Sato; Harumoto Yamada
Journal:  J Bone Miner Metab       Date:  2005       Impact factor: 2.626

7.  Soybean isoflavones preserve bone mass in hindlimb-unloaded mice.

Authors:  Fumie Sugiyama; Jian Wu; Maiko Fujioka; Junko Ezaki; Ken Takeda; Chisato Miyaura; Tatsuya Ishida; Kazuhiko Yamada; Yoshiko Ishimi
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

8.  Mechanical stress activates Smad pathway through PKCδ to enhance interleukin-11 gene transcription in osteoblasts.

Authors:  Shinsuke Kido; Rika Kuriwaka-Kido; Yuka Umino-Miyatani; Itsuro Endo; Daisuke Inoue; Hisaaki Taniguchi; Yasumichi Inoue; Takeshi Imamura; Toshio Matsumoto
Journal:  PLoS One       Date:  2010-09-29       Impact factor: 3.240

9.  Constitutively active parathyroid hormone receptor signaling in cells in osteoblastic lineage suppresses mechanical unloading-induced bone resorption.

Authors:  Noriaki Ono; Kazuhisa Nakashima; Ernestina Schipani; Tadayoshi Hayata; Yoichi Ezura; Kunimichi Soma; Henry M Kronenberg; Masaki Noda
Journal:  J Biol Chem       Date:  2007-05-11       Impact factor: 5.157

Review 10.  Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

Authors:  Ann E Kearns; Sundeep Khosla; Paul J Kostenuik
Journal:  Endocr Rev       Date:  2007-12-05       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.